JP2011524343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524343A5 JP2011524343A5 JP2011511643A JP2011511643A JP2011524343A5 JP 2011524343 A5 JP2011524343 A5 JP 2011524343A5 JP 2011511643 A JP2011511643 A JP 2011511643A JP 2011511643 A JP2011511643 A JP 2011511643A JP 2011524343 A5 JP2011524343 A5 JP 2011524343A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- chromatography
- iαip
- plasma fraction
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000005571 anion exchange chromatography Methods 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000011210 chromatographic step Methods 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 238000005406 washing Methods 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000011534 wash buffer Substances 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000037805 labour Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000001728 nano-filtration Methods 0.000 claims 2
- -1 plasma fraction Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13026908P | 2008-05-28 | 2008-05-28 | |
| US61/130,269 | 2008-05-28 | ||
| PCT/US2009/003291 WO2009154695A1 (en) | 2008-05-28 | 2009-05-28 | Preparation and composition of inter-alpha inhibitor proteins from blood |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015080358A Division JP6309915B2 (ja) | 2008-05-28 | 2015-04-09 | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524343A JP2011524343A (ja) | 2011-09-01 |
| JP2011524343A5 true JP2011524343A5 (enExample) | 2012-07-12 |
| JP5793076B2 JP5793076B2 (ja) | 2015-10-14 |
Family
ID=41434346
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511643A Active JP5793076B2 (ja) | 2008-05-28 | 2009-05-28 | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
| JP2015080358A Active JP6309915B2 (ja) | 2008-05-28 | 2015-04-09 | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
| JP2017124777A Pending JP2018008941A (ja) | 2008-05-28 | 2017-06-27 | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015080358A Active JP6309915B2 (ja) | 2008-05-28 | 2015-04-09 | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
| JP2017124777A Pending JP2018008941A (ja) | 2008-05-28 | 2017-06-27 | 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9139641B2 (enExample) |
| EP (1) | EP2291654B1 (enExample) |
| JP (3) | JP5793076B2 (enExample) |
| KR (3) | KR101828433B1 (enExample) |
| CN (2) | CN102112876B (enExample) |
| AU (1) | AU2009260822B2 (enExample) |
| BR (2) | BR122020017577B1 (enExample) |
| CA (1) | CA2726281C (enExample) |
| DK (1) | DK2291654T3 (enExample) |
| ES (1) | ES2673005T3 (enExample) |
| PT (1) | PT2291654T (enExample) |
| TR (1) | TR201808152T4 (enExample) |
| WO (1) | WO2009154695A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004289252C1 (en) | 2003-11-08 | 2013-06-20 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use |
| AU2009260822B2 (en) | 2008-05-28 | 2016-09-22 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from blood |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| US8841248B2 (en) | 2010-07-23 | 2014-09-23 | Baxter International Inc. | Manufacture of inter-alpha-inhibitor (IaIp) from plasma |
| KR101443257B1 (ko) * | 2011-10-18 | 2014-09-19 | 주식회사 종근당 | 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법 |
| WO2014039987A2 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| US20140206844A1 (en) * | 2013-01-18 | 2014-07-24 | Prothera Biologics | Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material |
| EP3041857B1 (en) * | 2013-09-04 | 2019-05-08 | EMD Millipore Corporation | Protein a chromatography |
| HUE057005T2 (hu) * | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| CN104138374A (zh) * | 2014-07-26 | 2014-11-12 | 滨州医学院 | 硫酸阿扎那韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用 |
| WO2017066683A1 (en) * | 2015-10-15 | 2017-04-20 | Plasma Technologies, Llc | Methods for extracting proteins from blood plasma |
| EP3512539A4 (en) | 2016-09-13 | 2020-07-29 | Prothera Biologics, Inc. | METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS |
| BR112019022358A2 (pt) * | 2017-04-25 | 2020-05-19 | Prothera Biologics Inc | métodos para quantificar proteínas inibidoras inter-alfa |
| US11040068B2 (en) * | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| US11634680B2 (en) * | 2017-11-20 | 2023-04-25 | Lonza Ltd | Process and system for propagating cell cultures while preventing lactate accumulation |
| EP3870147A4 (en) * | 2018-10-24 | 2022-08-31 | Prothera Biologics, Inc. | INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF |
| CN109900689B (zh) * | 2019-03-28 | 2021-12-10 | 复星诊断科技(长沙)有限公司 | 抗干扰膜及肝功能联合测试条 |
| AU2021377336A1 (en) | 2020-11-16 | 2023-07-06 | Prothera Biologics, Inc. | Methods for purifying inter-alpha inhibitor proteins |
| WO2023089503A1 (en) * | 2021-11-16 | 2023-05-25 | Takeda Pharmaceutical Company Limited | Inter-alpha inhibitor protein formulations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839298A (en) * | 1986-02-14 | 1989-06-13 | Akzo N.V. | Virus inactivating diluents used in immunoassays |
| ATE100210T1 (de) | 1988-11-01 | 1994-01-15 | Sanol Arznei Schwarz Gmbh | Lyophilisiertes mdm enthaltende zusammensetzung und verfahren zu deren herstellung. |
| GB8928501D0 (en) | 1989-12-18 | 1990-02-21 | Unilever Plc | Reagents |
| US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| FR2711371B1 (fr) | 1993-10-18 | 1995-12-29 | Aetsrn | Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu. |
| JPH0953775A (ja) | 1995-06-09 | 1997-02-25 | Kubota Corp | 埋設管路 |
| US6313091B1 (en) * | 1995-07-20 | 2001-11-06 | New York University | Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method |
| AU5134799A (en) | 1998-07-30 | 2000-02-21 | Human Genome Sciences, Inc. | 98 human secreted proteins |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US6489128B1 (en) | 2000-01-24 | 2002-12-03 | Rhode Island Hospital, A Lifespan Partner | Methods for detecting cancer of the central nervous system |
| US6660482B1 (en) | 2000-02-28 | 2003-12-09 | Rhode Island Hospital | Inter-alpha-trypsin inhibitor as a marker for sepsis |
| WO2002030983A2 (de) | 2000-10-13 | 2002-04-18 | Octapharma Ag | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung |
| EP1328260A2 (en) | 2000-10-18 | 2003-07-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
| CA2426102A1 (en) | 2000-12-08 | 2002-08-01 | Genentech, Inc. | Method of diagnosing and treating cartilaginous disorders |
| GB0114709D0 (en) * | 2001-06-15 | 2001-08-08 | Pfizer Ltd | Stabilised formulations of amlodipine maleate |
| US20030027848A1 (en) | 2001-06-15 | 2003-02-06 | Anne Billotte | Stabilized formulations |
| US20040009212A1 (en) * | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| KR20040098023A (ko) * | 2002-03-26 | 2004-11-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약물 미세입자 |
| BRPI0408323A (pt) * | 2003-03-14 | 2006-03-07 | Nirmal Mulye | processo para a preparação de compimidos de liberação prolongada |
| JP2007506681A (ja) | 2003-09-23 | 2007-03-22 | ピーディーエル バイオファーマ，インコーポレイティド | 抗ｉｌ−２受容体抗体による呼吸器疾患の治療 |
| AU2004289252C1 (en) * | 2003-11-08 | 2013-06-20 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use |
| PL1765866T3 (pl) | 2004-06-07 | 2014-06-30 | Therapure Biopharma Inc | Wydzielanie białek osocza lub surowicy |
| US7939282B2 (en) | 2004-10-21 | 2011-05-10 | Rhode Island Hospital | Methods for detecting sepsis |
| CN101160133B (zh) | 2004-11-05 | 2013-01-09 | 普罗瑟拉生物公司 | 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物 |
| CA2623940C (en) | 2005-09-27 | 2017-01-10 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| WO2008067655A1 (en) | 2006-12-05 | 2008-06-12 | Q6 Biomaterials Inc. | Biocompatible hydrogel-based scaffolds |
| AU2009260822B2 (en) | 2008-05-28 | 2016-09-22 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from blood |
| EP2313106B1 (en) | 2008-07-18 | 2016-03-30 | A1M Pharma AB | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
| AU2009325088B2 (en) | 2008-12-10 | 2014-06-19 | Duke University | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| US9562906B2 (en) | 2010-06-10 | 2017-02-07 | National University Of Singapore | Methods for detection of gastric cancer |
| US8841248B2 (en) | 2010-07-23 | 2014-09-23 | Baxter International Inc. | Manufacture of inter-alpha-inhibitor (IaIp) from plasma |
| WO2014039987A2 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| US20140206844A1 (en) | 2013-01-18 | 2014-07-24 | Prothera Biologics | Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material |
-
2009
- 2009-05-28 AU AU2009260822A patent/AU2009260822B2/en active Active
- 2009-05-28 KR KR1020167030334A patent/KR101828433B1/ko active Active
- 2009-05-28 JP JP2011511643A patent/JP5793076B2/ja active Active
- 2009-05-28 DK DK09767008.7T patent/DK2291654T3/en active
- 2009-05-28 US US12/995,141 patent/US9139641B2/en active Active
- 2009-05-28 WO PCT/US2009/003291 patent/WO2009154695A1/en not_active Ceased
- 2009-05-28 TR TR2018/08152T patent/TR201808152T4/tr unknown
- 2009-05-28 PT PT97670087T patent/PT2291654T/pt unknown
- 2009-05-28 EP EP09767008.7A patent/EP2291654B1/en active Active
- 2009-05-28 CA CA2726281A patent/CA2726281C/en active Active
- 2009-05-28 BR BR122020017577-0A patent/BR122020017577B1/pt active IP Right Grant
- 2009-05-28 CN CN200980129119.6A patent/CN102112876B/zh active Active
- 2009-05-28 KR KR1020107029406A patent/KR101714008B1/ko active Active
- 2009-05-28 CN CN201710066775.2A patent/CN106928346B/zh active Active
- 2009-05-28 BR BRPI0913949A patent/BRPI0913949A2/pt not_active Application Discontinuation
- 2009-05-28 ES ES09767008.7T patent/ES2673005T3/es active Active
- 2009-05-28 KR KR1020177027338A patent/KR20170116196A/ko not_active Ceased
-
2015
- 2015-04-09 JP JP2015080358A patent/JP6309915B2/ja active Active
- 2015-09-21 US US14/859,705 patent/US9758570B2/en active Active
-
2017
- 2017-02-22 US US15/439,328 patent/US10076559B2/en active Active
- 2017-06-27 JP JP2017124777A patent/JP2018008941A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524343A5 (enExample) | ||
| JP2009544279A5 (enExample) | ||
| MA30318B1 (fr) | Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4 | |
| JP2019520550A5 (enExample) | ||
| EA200400283A1 (ru) | Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции | |
| JP2019511469A5 (enExample) | ||
| JP2009537143A5 (enExample) | ||
| MA29672B1 (fr) | [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I | |
| JP2009537507A5 (enExample) | ||
| EP1730113A4 (en) | PROCESS FOR SYNTHESIS OF A CXCR4 ANTAGONIST | |
| EP1781800A4 (en) | PROCESS FOR PLASMID DNA FERMENTATION | |
| JP2012517826A (ja) | 凝固タンパクの精製手段と、その実施方法 | |
| JP2015510882A5 (enExample) | ||
| FR2853650B1 (fr) | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance | |
| RU2012120620A (ru) | Композиции, способы лечения и диагностика расстройств, связанных с аутоиммунными реакциями, и способы изготовления таких композиций | |
| FR2868414B1 (fr) | Procede de production d'alpha-alumine particulaire et apha-alumine particulaire produite par ce procede | |
| EP2373327A4 (en) | COMPOSITION WITH EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN 1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES | |
| KR20210107077A (ko) | 아데노바이러스 유형에 특이적인 dna 압타머 | |
| EP1637597A4 (en) | NUCLEIC INFUSION PROCESS | |
| ATE308895T1 (de) | Behandlung von infektionen in tieren | |
| DE50010648D1 (de) | Triazinonverbindungen zur behandlung von durch den befall mit parasitischen protozoen bedingten krankheiten | |
| Saei | Distribution of collagen adhesin gene among various types of Staphylococcus aureus strains associated with bovine mammary gland | |
| JP2005500015A5 (enExample) | ||
| EP1545556A4 (en) | NUCLEIC ACID AND CORROSIVE PROTEIN 98P4B6 FOR THE TREATMENT AND DETECTION OF CANCER | |
| CN108912051B (zh) | 一种含有4-咪唑基的谷氨酰胺酰基环化酶抑制剂 |